Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome

Annals of Oncology

Volumn 18, Issue 5, 2007, Pages 845-850

  Bergqvist, Jenny ^a   Ohd, J F ^a   Smeds, J ^a   Klaar, S ^a   Isola, J ^b   Nordgren, H ^c   Elmberger, G P ^a   Hellborg, H ^d   Bjohle, J ^a   Borg, A L ^a   Skoog, L ^a   Bergh, J ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Breast cancer; CISH; Diagnostic methods; HER2; Quantitative real time PCR; RNA expression profiles

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; RNA;

ARTICLE; BREAST CANCER; CANCER RELAPSE; CANCER SURVIVAL; CHROMOGENIC IN SITU HYBRIDIZATION; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; TISSUE SECTION; VALIDATION STUDY;

EID: 34447314200     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm059     Document Type: Article

References (31)

1. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005; 23: 4265-4274.
2. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672,
4. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005: 353: 1673-1684
5. Birner P, Oberhuber G, Stani J et al. Evaluation of the United States Food and Drug Administration-approved scoring and test system of her-2 protein expression in breast cancer, Clin Cancer Res 2001: 7: 1669-1675.
6. Ellis IO, Bartlett J, Dowsett M et al. Best practice No 176: Updated recommendations for HER2 testing in the UK. J Clin Pathol 2004, 57: 233-237.
7. Bankfalvi A, Simon R, Brandt B et al. Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number are protein overexpression in breast carcinoma tissues for diagnostic use. Histopathology 2000; 37: 411-419.
8. Hanna W, Kahn HJ, Trudeau M. Evaluation of HER-2/neu (erbB-2) status in breast cancer: From bench to bedside, Mod Pathol 1999; 12: 827-834.
9. Isola J, Tanner M, Forsyth A et al. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clip Cancer Res 2004; 10: 4793-4798.
10. Laakso M, Tanner M, Isola J. Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours. J Pathol 2006; 210: 3-9.
11. Irizarry RA, Warren D, Spencer F et al. Multiple-laboratory comparison of microarray platforms. Nat Methods 2005; 2: 345-350.
12. Larkin JE, Frank BC, Gavras H et al. Independence and reproducibility across microarray platforms. Nat Methods 2005; 2: 337-344.
13. Mackay IM, Arden KE, Nitsche A. Real-time PCR in virology, Nucleic Acids Res 2002; 30: 1292-1305.
14. Bergqvist J, Elmberger G, Ohd J et al. Activated ERK1/2 and phosphorylated oestrogen receptor alpha are associated with improved breast cancer survival in women treated with tamoxifen. Eur J Cancer 2006; 42: 1104-1112.
15. Sjogren S, Inganas M, Lindgren A et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998; 16: 462-469.
16. Carlsson J, Nordgren H, Sjostrom J et al. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 2004; 90: 2344-2348.
17. Tanner M, Gancberg D, Di Leo A et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Patrol 2000; 157: 1467-1472.
18. Egyhazi S, Bjohle J, Skoog L et al. Proteinase K added to the extraction procedure markedly increases RNA yield from primary breast tumors for use in microarray studies. Clin Chem 2004; 50: 975-976.
19. Pawitan Y, Bjohle J, Amler L et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: Derived and validated in two population-based cohorts. Breast Cancer Res 2005; 7: R953-R964.
20. Jimenez RE, Wallis T, Tabasczka P, Visscher DW. Determination of Her-2/ Neu status in breast carcinoma: Comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Med Pathol 2000; 13: 37-45.
21. Thomson TA, Hayes MM, Spinelli JJ et al. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Med Pathol 2001; 14: 1079-1086.
22. Press MF, Slamon DJ, Flom KJ et al. Evaluation of HER-2/neu gene amplification and overexpression: Comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002; 20: 3095-3105.
23. Ellis IO, Dowsett M, Bartlett J et al. Recommendations for HER2 testing in the UK. J Clin Patrol 2000; 53: 890-892.
24. Cronin M, Pho M, Dutta D et al. Measurement of gene expression in archival paraffin-embedded tissues: Development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 2004; 164: 35-42.
25. Ginestier C, Charafe-Jauffret E, Penault-Llorca F et al. Comparative multi-methodological measurement of ERBB2 status in breast cancer. J Pathol 2004; 202: 286-298.
26. Specht K, Richter T, Muller U et al. Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Patrol 2001; 158: 419-429.
27. Williams C, Norberg T, Ahmadian A et al. Assessment of sequence-based p53 gene analysis in human breast cancer: Messenger RNA in comparison with genomic DNA targets. Clin Chem 1998; 44: 455-462.
28. Gjerdrum LM, Sorensen BS, Kjelosen E et al. Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: An alternative method for HER-2/neu analysis, J Mol Diagn 2004: 6: 42-51.
29. Vinatzer U, Dampier B, Streubel B et al. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: Quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization. Clin Cancer Res 2005; 11: 8348-8357.
30. Esteva FJ, Sahin AA, Cristofanilli M et al, Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res 2005; 11: 3315-3319.
31. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer, N Engl J Med 2004; 351: 2817-2826.